

Moxetumomab pasudotox

Cat. No.:	HY-P99255
CAS No.:	1020748-57-5
Target:	Antibody-Drug Conjugates (ADCs); CD22
Pathway:	Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Moxetumomab pasudotox (CAT 8015) is anti-CD22 immunotoxin containing an anti-CD22 F _v and Pseudomonas exotoxin. CD22 is a cell surface receptor expressed on a variety of malignant B-cells. Moxetumomab pasudotox can be used in the research of hairy cell leukemia (HCL) ^{[1][2][3]} .								
In Vitro	Moxetumomab pasudotox (0-10 mg/mL, 66 h) reduces cell viability of BCP-ALL cells (determined by Annexin-V negative) ^[3] . The binding and internalization of MP/CD22 complexes is correlated with pre-B ALL cell line responses to MP ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.								
In Vivo	<p>Moxetumomab pasudotox (300 mg/kg, i.v., every other day) prolongs median survival in 697 cell model (P < 0.0001)^[3]. Moxetumomab pasudotox (0.4 mg/kg, i.v. three doses, every other day) clears the bone marrow (BM) from acute lymphoblastic leukemia (ALL), but disease relapses from discrete BM-sites in NSG mouse model^[4]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>NSG (NOD.Cg-Prkdc^{scid} Il2rg^{tm1Wjl}/SzJ) mouse model^[4]</td> </tr> <tr> <td>Dosage:</td> <td>0.4 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection (i.v.), three doses, every other day.</td> </tr> <tr> <td>Result:</td> <td>Survived much longer but died from ALL after 40 d. Reduced BM-infiltration to 4% on day 8.</td> </tr> </table>	Animal Model:	NSG (NOD.Cg-Prkdc ^{scid} Il2rg ^{tm1Wjl} /SzJ) mouse model ^[4]	Dosage:	0.4 mg/kg	Administration:	Intravenous injection (i.v.), three doses, every other day.	Result:	Survived much longer but died from ALL after 40 d. Reduced BM-infiltration to 4% on day 8.
Animal Model:	NSG (NOD.Cg-Prkdc ^{scid} Il2rg ^{tm1Wjl} /SzJ) mouse model ^[4]								
Dosage:	0.4 mg/kg								
Administration:	Intravenous injection (i.v.), three doses, every other day.								
Result:	Survived much longer but died from ALL after 40 d. Reduced BM-infiltration to 4% on day 8.								

REFERENCES

- [1]. Kreitman RJ, et al. Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial. *J Hematol Oncol.* 2021 Feb 24;14(1):35.
- [2]. hillon S. Moxetumomab Pasudotox: First Global Approval. *Drugs.* 2018 Nov;78(16):1763-1767.
- [3]. Kinjyo I, et al. Characterization of the anti-CD22 targeted therapy, moxetumomab pasudotox, for B-cell precursor acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2017 Nov;64(11):10.1002/pbc.26604.
- [4]. Müller F, et al. 5-Azacytidine prevents relapse and produces long-term complete remissions in leukemia xenografts treated with Moxetumomab pasudotox. *Proc Natl*

Acad Sci U S A. 2018 Feb 20;115(8):E1867-E1875.

[5]. Ksenia Matlawska-Wasowska, et al. Variability In Precursor B ALL Killing With Moxetumomab Pasudotox (CAT-8015) Linked To Differential Binding and Endocytic Trafficking. Blood (2013) 122 (21): 5022.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA